Evidence map›Paper›PMID 30905169›Full record

ArticleDrug delivery2019

A biocompatible reverse thermoresponsive polymer for ocular drug delivery.

Asitha Balachandra, Elsa C Chan, Joseph P Paul, Sze Ng, Vicki Chrysostomou, Steven Ngo, Roshan Mayadunne, Peter van Wijngaarden

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Asitha Balachandraa CSIRO Molecular Science & Health Technologies , Victoria , Australia.
Elsa C Chanb Centre for Eye Research Australia , Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Joseph P Paulb Centre for Eye Research Australia , Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Sze Ngb Centre for Eye Research Australia , Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Vicki Chrysostomoub Centre for Eye Research Australia , Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Steven Ngob Centre for Eye Research Australia , Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Roshan Mayadunnea CSIRO Molecular Science & Health Technologies , Victoria , Australia.
Peter van Wijngaardenb Centre for Eye Research Australia , Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Centre for Eye Research Australia · AUUniversity of Melbourne · AUCommonwealth Scientific and Industrial Research Organisation · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is a leading cause of vision loss, the treatment of which may require monthly intravitreal injections. This is a burden on patients and health services, and new delivery modalities that reduce injection frequency are required. To that end, we investigated the suitability of a novel reverse thermoresponsive polymer (RTP) as an ocular drug-delivery vehicle. In this work, we detail the structure and synthesis of a novel RTP, and determine drug release curves for two drugs commonly used in the treatment of AMD, bevacizumab and aflibercept. Biocompatibility of the RTP was assessed in vitro in human and rat cell lines and in vivo following intravitreal injection in rats. Bevacizumab demonstrated a more appropriate release profile than aflibercept, with 67% released within 14 days and 78% released in total over a 183-day period. No toxic effects of RTP were seen in human or rat cells in up to 14 days of co-culture with RTP. Following intravitreal injection, intraocular pressure was unaffected by the presence of RTP and no changes in retinal function or structure were observed at 1 week or 1 month post-injection. RTP injection did not cause inflammation, gliosis or apoptosis in the retina. This work demonstrates the potential suitability of the novel RTP as a sustained-release vehicle for ocular drug delivery for anti-neovascular therapies. Optimization of polymer chemistry for optimal drug loading and release is needed.

Indexed as

Drug Delivery SystemsAngiogenesis InhibitorsAnimalsBevacizumabCell LineDelayed-Action PreparationsDrug LiberationHumansIntraocular PressureIntravitreal InjectionsMacular DegenerationMalePolymersRatsRats, Long-EvansReceptors, Vascular Endothelial Growth FactorafliberceptAngiogenesis InhibitorsBevacizumabDelayed-Action PreparationsPolymersReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteinsanti-vascular endothelial growth factorintravitreal injectionmacular degenerationOcular drug deliveryreverse thermoresponsive polymer

Identifiers

PMID30905169
PMCPMC6442223
OpenAlexW2923957219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.